Nicholas Haft serves as Executive at Finch Therapeutics Group, Inc., where they oversee executive responsibilities. Since joining the company, Nicholas Haft has executed 8 insider transactions totaling $15.6M, demonstrating a bullish approach to their equity position. Their most recent transaction on Dec 20, 2021 involved purchasing 63,850 shares valued at $650.0K.
Nicholas Haft currently holds 4,056,907 shares of Finch Therapeutics Group, Inc. (FNCH), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Nicholas Haft has been a net buyer of FNCH stock. They have purchased $15.6M and sold $0 worth of shares.
Nicholas Haft's most recent insider trade was on Dec 20, 2021, when they purchased 63,850 shares at $10.18 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Mar 23, 2021 | FNCH | $0 | Conversion | 143,831 | $N/A | Discretionary |
| Mar 23, 2021 | FNCH | $0 | Conversion | 1,150,481 | $N/A | Discretionary |
| Mar 23, 2021 | FNCH | $15.0M | Purchase | 882,351 | $17.00 | Discretionary |
| Mar 23, 2021 | FNCH | $0 | Conversion | 1,064,466 | $N/A | Discretionary |
| Mar 23, 2021 | FNCH | $0 | Conversion | 212,893 | $N/A | Discretionary |
| Mar 23, 2021 | FNCH | $0 | Conversion | 366,093 | $N/A | Discretionary |